INTERVENTION 1:	Intervention	0
Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W	Intervention	1
ph	UO:0000196	0-2
Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W	Intervention	2
INTERVENTION 2:	Intervention	3
Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W	Intervention	4
ph	UO:0000196	0-2
Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W	Intervention	5
Main Inclusion Criteria:	Eligibility	0
Signed informed consent prior to any procedures	Eligibility	1
Phase Ib part: Adult patients with advanced melanoma, endometrial carcinoma, pancreatic or TNBC, with measurable or non-measurable disease who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.	Eligibility	2
adult	EFO:0001272	15-20
melanoma	HP:0002861,DOID:1909	44-52
endometrial carcinoma	HP:0012114,DOID:2871	54-75
disease	DOID:4,OGMS:0000031	131-138
Phase II part: Adult patients with advanced solid tumors who have received standard therapy (no more than 3 prior lines of treatment) or are intolerant of standard therapy, have progressed following their last prior therapy, and fit into one of the following groups:	Eligibility	3
adult	EFO:0001272	15-20
Group 1: TNBC who did not receive prior anti-PD-1/PD-L1 treatment	Eligibility	4
group	CHEBI:24433	0-5
Group 2: Pancreatic adenocarcinoma who did not receive prior anti-PD-1/PD-L1 treatment	Eligibility	5
group	CHEBI:24433	0-5
pancreatic adenocarcinoma	HP:0006725,DOID:4074	9-34
Group 3: Endometrial carcinoma who did not receive prior anti-PD-1/PD-L1 treatment	Eligibility	6
group	CHEBI:24433	0-5
endometrial carcinoma	HP:0012114,DOID:2871	9-30
Group 4: Melanoma who progressed on prior anti-PD-1/PD-L1 treatment.	Eligibility	7
group	CHEBI:24433	0-5
melanoma	HP:0002861,DOID:1909	9-17
Main Exclusion Criteria:	Eligibility	8
Patients with the following:	Eligibility	9
Symptomatic central nervous system (CNS) metastases or those requiring local CNS-directed therapy.	Eligibility	10
central nervous system	UBERON:0001017	12-34
Abnormal liver, renal, or blood lab values.	Eligibility	11
liver	UBERON:0002107	9-14
blood	UBERON:0000178	26-31
Impaired cardiac function or clinically significant cardiac disease.	Eligibility	12
function	BAO:0003117,BFO:0000034	17-25
disease	DOID:4,OGMS:0000031	60-67
Active autoimmune disease or documented autoimmune disease within 3 years of screening.	Eligibility	13
active	PATO:0002354	0-6
autoimmune disease	DOID:417	7-25
autoimmune disease	DOID:417	40-58
Active infection requiring antibiotic therapy.	Eligibility	14
active	PATO:0002354	0-6
Known HIV, active hepatitis B or C virus.	Eligibility	15
active	PATO:0002354	11-17
hepatitis b	DOID:2043	18-29
virus	BAO:0000232	35-40
Concurrent malignant disease.	Eligibility	16
disease	DOID:4,OGMS:0000031	21-28
Patients who received systemic anticancer therapy, major surgery, or radiotherapy within 2 weeks of study treatment, or live vaccines within 4 weeks of study treatment.	Eligibility	17
surgery	OAE:0000067	57-64
radiotherapy	OAE:0000235	69-81
Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy.	Eligibility	18
chronic	HP:0011010	19-26
steroid	CHEBI:35341	51-58
Patients who used hematopoietic colony-stimulating growth factors within 2 weeks of study treatment.	Eligibility	19
growth	GO:0040007	51-57
Outcome Measurement:	Results	0
Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety	Results	1
Phase Ib: To characterize the safety and tolerability of MCS110 in combination with PDR001 in patients with advanced solid malignancies and to identify a recommended dose combination for Phase II.	Results	2
Time frame: From start of treatment to a maximum timeframe of 116.4 weeks for phase Ib	Results	3
time	PATO:0000165	0-4
time	PATO:0000165	49-53
Results 1:	Results	4
Arm/Group Title: Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W	Results	5
ph	UO:0000196	17-19
Arm/Group Description: Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W	Results	6
Overall Number of Participants Analyzed: 6	Results	7
Measure Type: Count of Participants	Results	8
Unit of Measure: Participants  Adverse events (AEs) - all grades: 6 100.0%	Results	9
Adverse events - Treatment-related - all grades: 6 100.0%	Results	10
Serious Adverse Events (SAEs) - all grades: 3  50.0%	Results	11
SAEs - Treatment-related - all grades: 0   0.0%	Results	12
Fatal SAEs - all grades: 0   0.0%	Results	13
Fatal SAEs - Treatment-related - all grades: 0   0.0%	Results	14
AEs leading to discontinuation - all grades: 0   0.0%	Results	15
AEs leading to discontinuation - Treatment-related - all grades: 0   0.0%	Results	16
AEs leading to dose adjustment / interruption - all grades: 4  66.7%	Results	17
AEs requiring additional therapy - all grades: 6 100.0%	Results	18
Results 2:	Results	19
Arm/Group Title: Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W	Results	20
ph	UO:0000196	17-19
Arm/Group Description: Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W	Results	21
Overall Number of Participants Analyzed: 12	Results	22
Measure Type: Count of Participants	Results	23
Unit of Measure: Participants  Adverse events (AEs) - all grades: 12 100.0%	Results	24
Adverse events - Treatment-related - all grades: 12 100.0%	Results	25
Serious Adverse Events (SAEs) - all grades: 4  33.3%	Results	26
SAEs - Treatment-related - all grades: 1   8.3%	Results	27
Fatal SAEs - all grades: 0   0.0%	Results	28
Fatal SAEs - Treatment-related - all grades: 0   0.0%	Results	29
AEs leading to discontinuation - all grades: 0   0.0%	Results	30
AEs leading to discontinuation - Treatment-related - all grades: 0   0.0%	Results	31
AEs leading to dose adjustment / interruption - all grades: 4  33.3%	Results	32
AEs requiring additional therapy - all grades: 12 100.0%	Results	33
Adverse Events 1:	Adverse Events	0
Total: 3/6 (50.00%)	Adverse Events	1
Anaemia 0/6 (0.00%)	Adverse Events	2
Abdominal pain 1/6 (16.67%)	Adverse Events	3
abdominal pain	HP:0002027	0-14
Ascites 0/6 (0.00%)	Adverse Events	4
ascites	HP:0001541	0-7
Constipation 0/6 (0.00%)	Adverse Events	5
constipation	HP:0002019,DOID:2089	0-12
Dyspepsia 1/6 (16.67%)	Adverse Events	6
dyspepsia	HP:0410281	0-9
Gastric haemorrhage 0/6 (0.00%)	Adverse Events	7
Gastrointestinal haemorrhage 0/6 (0.00%)	Adverse Events	8
Haemoperitoneum 0/6 (0.00%)	Adverse Events	9
Intestinal obstruction 0/6 (0.00%)	Adverse Events	10
intestinal obstruction	HP:0005214,DOID:8437	0-22
Intestinal perforation 1/6 (16.67%)	Adverse Events	11
intestinal perforation	HP:0031368,DOID:2074	0-22
Large intestinal obstruction 1/6 (16.67%)	Adverse Events	12
intestinal obstruction	HP:0005214,DOID:8437	6-28
Adverse Events 2:	Adverse Events	13
Total: 4/12 (33.33%)	Adverse Events	14
Anaemia 0/12 (0.00%)	Adverse Events	15
Abdominal pain 0/12 (0.00%)	Adverse Events	16
abdominal pain	HP:0002027	0-14
Ascites 0/12 (0.00%)	Adverse Events	17
ascites	HP:0001541	0-7
Constipation 0/12 (0.00%)	Adverse Events	18
constipation	HP:0002019,DOID:2089	0-12
Dyspepsia 0/12 (0.00%)	Adverse Events	19
dyspepsia	HP:0410281	0-9
Gastric haemorrhage 0/12 (0.00%)	Adverse Events	20
Gastrointestinal haemorrhage 0/12 (0.00%)	Adverse Events	21
Haemoperitoneum 0/12 (0.00%)	Adverse Events	22
Intestinal obstruction 0/12 (0.00%)	Adverse Events	23
intestinal obstruction	HP:0005214,DOID:8437	0-22
Intestinal perforation 0/12 (0.00%)	Adverse Events	24
intestinal perforation	HP:0031368,DOID:2074	0-22
Large intestinal obstruction 0/12 (0.00%)	Adverse Events	25
intestinal obstruction	HP:0005214,DOID:8437	6-28
